Medindia

Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update

SAN DIEGO and INDIANAPOLIS, Nov. 2, 2009 Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following statement in response to the U.S. Food and Drug ...
FiercePharma

Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Present

SAN DIEGO, June 24, 2011 /PRNewswire/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective analysis of more than 778,000 ...
FiercePharma

BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...
CBS News

How a Pitch for Amylin's Diabetes Drug Byetta Actually Helped Its Rivals

Amylin Pharmaceuticals and Eli Lilly had a broad presence at the 70 th annual American Diabetes Association convention held in late June. Unfortunately, clinical data presented at the conference for ...
FierceBiotech

BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes

SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced ...
FierceBiotech

Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission

SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that ...
Reuters

Amylin reports positive data from Byetta study

Study over 24 weeks on patients with type 2 diabetes Says exenatide once-weekly shows superior glucose control Dec 15 (Reuters) - Amylin Pharmaceuticals Inc reported positive data from a study that ...
Reuters

CORRECTED - CORRECTED-Amylin says new diabetes injection meets main goal

Oct 31 (Reuters) - Amylin Pharmaceuticals Inc said a study of its once-weekly exenatide long-acting release injection to treat type 2 diabetes met its main goal of glucose control. The study, which is ...
MarketWatch

Amylin group: Byetta injection improves glucose control

SAN FRANCISCO (MarketWatch) -- Amylin Pharmaceuticals Inc. , Eli Lilly and Co. and Alkermes Inc. said after Monday's closing bell said preliminary results from a Phase II study of Byetta injection ...
Healthline

Side Effects of Byetta: What You Need to Know

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes. Byetta can cause side effects that range from mild to serious. Examples include nausea and vomiting. The active ...
Medindia

Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission

SAN DIEGO and INDIANAPOLIS, Dec. 8 AmylinPharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)today announced that the U.S. Food and Drug Administration (FDA) is continuingwith ...